AJOVY is indicated for the preventive treatment of migraine in adults.

You can also browse the topics below to find what you are looking for.

DRUG-DRUG INTERACTIONS WITH AJOVY ARE UNLIKELY1

CYTOCHROME P450 METABOLISM OF AJOVY vs ORAL RECEPTOR BLOCKERS

CONCOMITANT DRUG USE CON-
COMITANT
DRUG USE

AJOVY® (fremanezumab-vfrm)1

 

AJOVY IS NOT METABOLIZED BY CYP4501

 Nurtec® (rimegepant)2 Qulipta® (atogepant)3
CYP3A4 Inhibitors    
CYP3A Inducers    
P-gp Inhibitors    
OATP Inhibitors    
 

TREATMENT NOT METABOLIZED BY PATHWAY

 

TREATMENT METABOLIZED BY PATHWAY

 

NO CONCLUSIVE INFORMATION AVAILABLE

This information should not be construed to imply any difference in safety, efficacy, or other clinical outcome.

Patients may be taking other substances that affect CYP450 metabolism; therefore, it is important to be aware of drug-drug interactions when taking certain oral medications.

To see a list of at least 700 medications that interact with CYP450 and may cause drug-drug interactions with your patients’ concomitant treatments, see the Flockhart Table.TM AJOVY is not metabolized by CYP450, therefore drug-drug interactions are unlikely.1

Nurtec® is a registered trademark owned or licensed by Pfizer Inc. Qulipta® is a registered trademark owned or licensed by AbbVie.

NOW is the time for AJOVY
​

OATP: Organic anion transporting polypeptide.

References: 1. AJOVY® (fremanezumab-vfrm) injection Current Prescribing Information. North Wales, PA: Teva Pharmaceuticals USA, Inc. 2. Nurtec® ODT (rimegepant) orally disintegrating tablets. Prescribing Information. New York, NY. Pfizer Inc. 3. QULIPTA® (atogepant) tablets. Prescribing Information. North Chicago, IL. AbbVie Inc.